Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years’ Real-World Clinical Outcomes

QR Code

Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years’ Real-World Clinical Outcomes

Faye Horner, Peck Lin Lip, Bashar R Mohammed, William Fusi-Rubiano, Eesha Gokhale, Bushra Mushtaq, Randhir Chavan Birmingham & Midland Eye Centre, Birmingham, UKCorrespondence: Randhir ChavanBirmingham & Midland Eye Centre, Sandwell & West Birmingham Hospitals NHS Trust, City...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Horner F, Lip PL, Mohammed BR, Fusi-Rubiano W, Gokhale E, Mushtaq B, Chavan R
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2021
Sujets:	amd ranibizumab aflibercept protocols prn treat & extend Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/3daaacb669af4205b2d6cba82c97e077
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
par: Khanani AM, et autres
Publié: (2019)

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
par: Amoaku W, et autres
Publié: (2018)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
par: Garweg JG
Publié: (2019)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
par: Koike N, et autres
Publié: (2019)

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
par: Taipale C, et autres
Publié: (2018)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
par: Cvetkova NP, et autres
Publié: (2016)

Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
par: Apsangikar P, et autres
Publié: (2021)

Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
par: Horner F, et autres
Publié: (2019)

Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
par: Patel PJ, et autres
Publié: (2017)

Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance
par: Dirani A, et autres
Publié: (2018)

Physician, patient, and caregiver experience of different wet age-related macular degeneration anti-VEGF treatment regimens in Japan: a qualitative assessment
par: Iida T, et autres
Publié: (2016)

Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis
par: Kiss S, et autres
Publié: (2018)

Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2
par: Narayanan R, et autres
Publié: (2016)

Adding a Corticosteroid or Switching to Another Anti-VEGF in Insufficiently Responsive Wet Age-Related Macular Degeneration
par: Kaya C, et autres
Publié: (2019)

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
par: Nixon DR, et autres
Publié: (2017)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
par: Nudleman E, et autres
Publié: (2016)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
par: Veluswamy B, et autres
Publié: (2020)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
par: Fouda SM, et autres
Publié: (2017)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
par: Pessoa B, et autres
Publié: (2021)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
par: Canan H, et autres
Publié: (2014)

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2)
par: Jumper JM, et autres
Publié: (2018)

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
par: Xiu-Xian Wang, et autres
Publié: (2021)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
par: Hirakata T, et autres
Publié: (2016)

Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice
par: Horner F, et autres
Publié: (2020)

OCT Angiography-based Evaluation of the Choriocapillaris in Neovascular Age-related Macular Degeneration
par: Varsha Pramil, et autres
Publié: (2021)

Immediate sequential bilateral intravitreal injections: an Indian perspective
par: Tripathy K
Publié: (2017)

Visual Outcome and Treatment Frequency of Anti-VEGF Therapy Using the Treat-and-Extend and Treatment Cessation Regimen for Exudative Age-Related Macular Degeneration and Pachychoroid Neovasculopathy
par: Kinoshita T, et autres
Publié: (2021)

Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options
par: Veritti D, et autres
Publié: (2021)

Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion
par: Tagami M, et autres
Publié: (2017)

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
par: Azuma K, et autres
Publié: (2018)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
par: Alsaedi NG, et autres
Publié: (2021)

Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model
par: Zhuang Cui, et autres
Publié: (2021)

Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
par: Sakanishi Y, et autres
Publié: (2017)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
par: Nixon DR, et autres
Publié: (2018)

Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial
par: Russo A, et autres
Publié: (2018)

Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis
par: Cui C, et autres
Publié: (2017)

Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration
par: Elfandi S, et autres
Publié: (2021)

Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
par: Mehta H, et autres
Publié: (2020)

Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
par: Spooner K, et autres
Publié: (2017)

Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation
par: Maruyama-Inoue M, et autres
Publié: (2019)